Patents by Inventor David B. Rozema

David B. Rozema has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
    Patent number: 8426554
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 23, 2013
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hoffmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Compositions for targeted delivery of siRNA
    Patent number: 8313772
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: November 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield
  • Polyconjugates for In Vivo Delivery of Polynucleotides
    Publication number: 20120230938
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: February 8, 2012
    Publication date: September 13, 2012
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. ROZEMA, Darren H. WAKEFIELD, David L. LEWIS, Jason KLEIN, So WONG, Jon A. WOLFF, James E. HAGSTROM
  • Endosomolytic polymers
    Patent number: 8217015
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: July 10, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield
  • In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages
    Publication number: 20120172412
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Application
    Filed: December 23, 2011
    Publication date: July 5, 2012
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Endosomolytic polymers
    Patent number: 8211468
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: July 3, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Jon A. Wolff, James E. Hagstrom, Kirk Ekena
  • Peptide-Based In Vivo siRNA Delivery System
    Publication number: 20120165393
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Application
    Filed: December 15, 2011
    Publication date: June 28, 2012
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffman, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA
    Publication number: 20120157509
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Application
    Filed: December 15, 2011
    Publication date: June 21, 2012
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B. Rozema, David L. Lewis, Darren H. Wakefield
  • Membrane active heteropolymers
    Patent number: 8138383
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Polyconjugates for in vivo delivery of polynucleotides
    Patent number: 8137695
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, James E. Hagstrom, Jason Klein, David L. Lewis, Sean D. Monahan, Darren H. Wakefield, Jon A. Wolff, So Wong
  • Endosomolytic poly(acrylate) polymers
    Patent number: 8017109
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 13, 2011
    Assignee: Roche Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Endosomolytic poly(vinyl ether) polymers
    Patent number: 8008355
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Compositions for Targeted Delivery of siRNA
    Publication number: 20110207799
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 25, 2011
    Applicant: ROCHE MADISON INC.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Membrane active heteropolymers
    Patent number: 7985406
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: July 26, 2011
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Membrane active polymers
    Patent number: 7871818
    Abstract: We describe a class of polymaleic anhydride polymers capable of disrupting cell membranes. Co-delivery of these polymers with biologically active compounds increases cellular cytoplasmic delivery of the compounds.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: January 18, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield
  • Reversible attachment of a membrane active polymer to a polynucleotide
    Patent number: 7816337
    Abstract: Described is a process for delivering a biologically active compound to a cell by reversibly linking the compound to a membrane active polymer. In particular, polymer-polynucleotide conjugates are described. Methods for reversibly modifying the polymers to decrease cellular toxicity and improve efficacy are provided.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: October 19, 2010
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield, Jon A Wolff, Kirk Ekena, James E. Hagstrom
  • Polyvinylethers for delivery of polynucleotides to mammalian cells
    Patent number: 7682626
    Abstract: A class of polymers for delivery of polynucleotides to cells in described. More specifically, amphiphilic polyvinylethers and compositions containing amphiphilic polyvinylethers are described.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: March 23, 2010
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield
  • Membrane Active Heteropolymers
    Publication number: 20090048410
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: February 19, 2009
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Process of making a compound by forming a polymer from a template drug
    Patent number: 7482160
    Abstract: A method of forming polymers in the presence of nucleic acid using template polymerization. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte complex.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: January 27, 2009
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, David B. Rozema, Vladimir Trubetskoy, Paul M. Slattum, Jon A. Wolff, Vladimir G. Budker, James E. Hagstrom, Lisa J. Hanson
  • Membrane Active Heteropolymers
    Publication number: 20090023890
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: January 22, 2009
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom